Methods of synthesizing and depositing the omnibus advanced materials

The "dielectric, ferroelectric & wide-bandgap oxides" portfolio contains a structural weakness shared by nearly every multi-composition patent family: individual composition claims can be designed around by a competitor who changes the formula or the synthesis route simultaneously. A cross-family method-of-making claim closes that gap. This asset is precisely that — a single claim vessel that captures the synthesis and deposition routes for every composition in the portfolio under one priority date, making it substantially harder for a licensee or competitor to exploit a composition covered elsewhere while escaping the method umbrella. The claim is enabled by an unusually deep empirical record: more than 240 published exact-composition recipes have been identified and catalogued to demonstrate that the synthesis methods described are not merely prophetic but reflect established, reproducible laboratory practice across the community. This is a meaningful enablement anchor. Patent offices frequently challenge method claims that span broad compositional families on the grounds that undue experimentation would be required to practice the full scope; the 240-plus recipe census is a direct answer to that objection, showing that the process windows described — for solid-state synthesis, single-crystal growth, PLD, sputtering, MOCVD, ALD, sol-gel, and MBE — are already documented in the prior art for the specific compositions claimed. Strategically, this asset functions as a defensive wrapper and portfolio multiplier rather than a standalone commercial asset. Its value is inseparable from the composition and use claims in the broader portfolio. A buyer acquiring rights to the composition families gains, with this method claim, the ability to block or license every integration route those compositions might travel through — from bulk pellet synthesis to atomic-layer deposition of a thin-film gate oxide. That is a materially different commercial position than owning composition claims alone.

This is a process-class claim rather than a composition claim, so there is no single chemical formula or crystal structure at its center. Instead, the technical substance lies in the breadth and specificity of the process windows it captures. The claim covers at least seven distinct deposition and synthesis modalities: solid-state synthesis (high-temperature ceramic processing of oxide powders), single-crystal growth (flux or Czochralski-type methods where applicable), pulsed laser deposition (PLD), RF/DC magnetron sputtering, metal-organic chemical vapor deposition (MOCVD), atomic layer deposition (ALD), sol-gel / chemical solution deposition (CSD), and molecular beam epitaxy (MBE). Sub-methods extended through companion claims include ALD-specific process sequences, ion-slicing (a hydrogen-implantation and layer-transfer technique used to produce free-standing or bonded single-crystal films), and post-deposition sulfurization — a chalcogen-exchange anneal relevant to specific wide-bandgap variants in the portfolio. Post-deposition processing steps including crystallization anneals, electrode patterning, edge termination, and contact metallization are also captured, meaning the claim follows a material from precursor through to a finished device layer. The breadth of this claim is technically defensible because the underlying portfolio spans multiple well-studied oxide families — dielectrics, ferroelectrics, and wide-bandgap semiconductors — for which the synthesis community has generated a dense, documented record. The internal census of 243 exact-composition published recipes constitutes a process-window map: for each composition in scope, at least one peer-reviewed or patent-documented synthesis route exists at the conditions specified. This is significant from an enablement standpoint because it grounds the claim in demonstrated prior practice, reducing exposure to arguments that the specification fails to enable the full scope. Family-specific process windows are additionally detailed in the patent specification for each subgroup, providing fallback claim support at finer compositional granularity. From a materials-science perspective, the technical challenge these methods address is the notorious sensitivity of complex oxide thin films to stoichiometry, oxygen partial pressure, substrate choice, and thermal budget. Perovskite ferroelectrics, for instance, require precise A-site to B-site cation ratios and post-deposition oxygen anneals to achieve ferroelectric polarization; wide-bandgap oxides such as Ga2O3 polymorphs are highly sensitive to growth temperature and ambient oxygen activity. The claim's value is partly that it is family-aware: the process windows are not described as a single monolithic recipe but as modality-specific conditions indexed to the composition subgroups, which reflects how these materials actually behave in the lab. This architecture makes the claim harder to design around by merely tweaking a deposition temperature, because the specification discloses multiple modalities and the conditions appropriate to each. One technical limitation is worth stating plainly: the claim does not introduce new synthesis chemistry. Every method covered exists in the published literature. The inventive contribution is in the systematic cross-family codification of those methods as applied to the specific compositions claimed elsewhere in the portfolio, combined with the enablement record that ties process windows to exact compositions. This is a legitimate form of method claiming — particularly for portfolio protection — but a sophisticated buyer should understand that the claim's strength derives from its relationship to the composition claims rather than from any independently novel process step.

The market context for this asset is best understood at the portfolio level, because the method claim has no standalone commercial life — it is a capture mechanism for value that originates in the composition and use claims. The relevant commercial arenas are the markets for dielectric materials (high-k gate dielectrics, capacitor materials for DRAM and MLCCs), ferroelectric materials (FeRAM, neuromorphic memory, piezoelectric actuators, next-generation non-volatile memory), and wide-bandgap oxide semiconductors (power electronics, RF devices, UV photodetectors). These are collectively large and growing markets. The global market for advanced dielectric and ferroelectric materials in semiconductor applications is in the multi-billion-dollar range annually, driven by continued miniaturization, the proliferation of power conversion electronics in EVs and data centers, and the expansion of capacitive and memory device density. Wide-bandgap power semiconductors are themselves a high-growth segment as SiC and GaN incumbents face margin pressure from oxide-based alternatives still under development. A method-of-making claim captures commercial value in this context through two mechanisms. First, it provides a basis for licensing any manufacturer who practices a covered deposition route on a covered composition — including foundries and OSAT facilities that would not themselves hold composition rights but would practice the synthesis. Second, it provides blocking power against a design-around strategy in which a competitor accepts a composition license but attempts to use an unlicensed process variant. The royalty logic for method claims in materials manufacturing typically tracks production volume or wafer starts rather than device performance, which makes revenue modeling more predictable than performance-based royalties tied to efficiency or breakdown voltage. No specific TAM estimate for the method claim alone is provided in the underlying data, and inventing one would not be appropriate; the commercial framing is that this claim derives and amplifies value from the portfolio it wraps.

single method vessel preserving priority for every family's synthesis/integration route

method tied to the corresponding family's process window

The most natural acquirers or licensees for this asset are entities that are simultaneously acquiring or licensing the composition and use claims in the broader portfolio, since the method claim's value is structurally dependent on those relationships. Integrated device manufacturers in the advanced memory, power electronics, or RF sectors who want a defensible position across the full synthesis-to-device stack — not just composition rights — are the primary targets. Foundries operating advanced oxide deposition lines (including MOCVD and ALD lines for high-k dielectrics or ferroelectrics) are a secondary licensing target, particularly as the industry moves toward integrating ferroelectric hafnium oxide and wide-bandgap semiconductor layers into back-end-of-line and power device flows. Materials and equipment companies that provide ALD precursors, PLD targets, or sputtering source materials for oxide thin films may also find defensive or cross-licensing value here, since the method claim creates a potential assertion surface against their customers that they may prefer to neutralize through a portfolio-level agreement. Government-funded research institutions or national laboratories building IP positions in wide-bandgap oxide power electronics — a segment with active U.S., European, and Japanese government investment programs — represent a third buyer class, particularly for licensing structures that allow continued academic practice while securing commercial rights for downstream industrial partners.

The primary risk for this asset is structural dependency: the method claim generates little to no standalone licensing leverage in a scenario where the companion composition and use claims are weakened, invalidated, or successfully designed around. A sophisticated defendant in a method-only assertion could argue that the compositions they are processing are not within the scope of the portfolio families, collapsing the method claim's reach without directly challenging the method steps themselves. This is not a fatal flaw — it reflects the intended role of the asset as a wrapper rather than a lead claim — but it means a buyer must underwrite the strength of the composition claims to properly value the method claim. The path to de-risking is clear. First, complete the wet-lab coupon program: first-party reduced-to-practice demonstrations per family transform the enablement record from literature-anchored to experimentally anchored, which materially strengthens the claim against any future enablement challenge. Second, maintain the structural linkage between this method claim and the article claims through claim drafting and prosecution, so that challenges to one group require engagement with the others. Third, conduct production-scale FTO diligence for any specific commercial implementation to confirm that the equipment and precursor choices stay within the clean process windows identified. These are manageable, well-defined steps that fit naturally into the maturation roadmap of the broader portfolio.